Emphysema Treatment Market Size Analysis Report - Market Share, Forecast Trends and Outlook (2025-2034)
Description
The emphysema treatment market was valued at USD 4.65 billion in 2024, driven by the rising incidence of chronic lung conditions and the growing focus on respiratory health across the 8 major markets. The market is anticipated to grow at a CAGR of 5.7% during the forecast period 2025-2034 to reach a value of USD 7.66 billion by 2034.
Emphysema Treatment Market Outlook
Emphysema (a type of chronic obstructive pulmonary disease (COPD)) is a lung condition that leads to shortness of breath due to the damage caused to the air sacs (alveoli) in the lungs. The increase in the number of tobacco smokers is driving the growth of the market. The growing prevalence of chronic lung disorders and the availability of advanced diagnostic facilities are resulting in the increased demand for emphysema treatments. Moreover, factors such as increasing sedentary lifestyles, growing urbanization and industrialization, and rising pollution levels are further propelling market expansion. Additionally, the growing research and development activities and the advancements in the medical sector are expected to impact the market dynamics positively.
Emphysema Treatment Market Growth Drivers
Increasing Prevalence of Emphysema Drives Market Growth
In the United States, around 14 million people are affected by emphysema, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is reported slightly lower in white female smokers and African Americans. The severity of the emphysema is substantially higher in coal worker pneumoconiosis, irrespective of smoking status. The rising incidence of emphysema, as a result of an increase in cigarette smoking and environmental pollution, is expected to fuel the market growth.
Emphysema Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Launch of Generic Medications to Affect the Market Landscape Significantly
The increasing availability of generic treatments is projected to impact the market growth. For instance, in July 2023 , Viatris Inc. (an American global pharmaceutical company) and Kindeva Drug Delivery L.P. (a pharmaceutical contract development and manufacturing organization (CDMO)) announced the launch of its drug-device combination product Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, which is the first generic version of AstraZeneca’s Symbicort. Breyna is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD), including emphysema and/or chronic bronchitis.
Increased Adoption of Combination Therapies Poised to Augment Emphysema Treatment Market Demand
One of the major market trends is the rising preference for combination therapies, such as long-acting bronchodilators paired with inhaled corticosteroids. These combination treatments not only help in managing the symptoms more effectively but can also slow the progression of emphysema and the frequency of exacerbations, thereby improving the patient’s quality of life. The rising integration of combination therapies into treatment protocols is likely to augment the market demand.
Increased Research to Elevate the Emphysema Treatment Market Value
In January 2024 , a study published in JCI Insight revealed that a novel KF4 antibody that works by blocking chymotrypsin-like elastase 1 (CELA1) can significantly reduce lung damage as a result of diseases such as chronic obstructive pulmonary disease (COPD) and age-related emphysema in mice. Such research activities that show potential in slowing emphysema progression are set to elevate the market value in the coming years.
Advancements in Treatment Options to Boost Emphysema Treatment Market Size
The rising advancements in treatment options are poised to shape the market landscape positively. Lung volume reduction surgeries (LVRS) and procedures like endobronchial valve placement are rising in popularity as they are less invasive in nature compared to traditional methods for the treatment of severe emphysema. In addition, the emergence of biologic therapies targeting specific inflammatory pathways is anticipated to boost the market size in the forecast period.
Emphysema Treatment Market Segmentation
Market Breakup by Type
The Type Segment is Anticipated to Witness Substantial Growth
Based on the type, the market is segmented into centriacinar, panacinar, and paraseptal, among others. Centriacinar dominates the market share as it is the most common type of emphysema, starting in the respiratory bronchioles and affecting the upper half of the lungs. This emphysema type is usually associated with long-term cigarette smoking. On the other hand, panacinar emphysema is caused by a rare genetic disease called homozygous alpha-1 antitrypsin deficiency. It typically occurs in the lower half of the lungs.
Emphysema Treatment Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the major markets for emphysema treatment owing to the high prevalence of chronic obstructive pulmonary disease (COPD) and increasing environmental pollution in the region. The availability of advanced treatments such as minimally invasive procedures and biologic therapies also benefits the market growth. Moreover, the presence of a robust regulatory framework and increasing focus on respiratory health is poised to aid market expansion in the country.
Leading Players in the Emphysema Treatment Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer Inc.
American multinational pharmaceutical industry company Pfizer is one of the leading players in the market. SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is a prescription medication developed by Pfizer that helps in the management of symptoms of chronic obstructive pulmonary disease (COPD) including emphysema.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, has a prominent presence in the market. The company is engaged in introducing new treatments for emphysema by investing in the clinical development of potential medications such as the monoclonal antibody astegolimab.
Mylan N.V.
Mylan N.V., a global healthcare company developing generic and specialty pharmaceuticals, merged with Pfizer's off-patent medicine division (Upjohn) to form Viatris. The company is focused on advancing respiratory care by leveraging strategic partnerships and collaborations with other market players.
Fresenius Kabi AG
Headquartered in Bad Homburg, Germany, Fresenius Kabi AG is a key market player that manufactures and commercializes infusion therapy and clinical nutrition products.
Other key players in the market include Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc, Bayer AG, Intersect ENT, Inc., and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in the Emphysema Treatment Market Report
Emphysema Treatment Market Outlook
- The increasing cases of emphysema, driven by factors like smoking, environmental pollutants, and the growing aging population, is a primary driver of the market.
- The rising emphasis on respiratory health and government support for early diagnosis and management of chronic respiratory diseases is anticipated to elevate the market value during the forecast period.
- The expanding research into regenerative medicine and stem cell therapies is a significant market trend that is attracting substantial investment from both the public and private sectors.
Emphysema (a type of chronic obstructive pulmonary disease (COPD)) is a lung condition that leads to shortness of breath due to the damage caused to the air sacs (alveoli) in the lungs. The increase in the number of tobacco smokers is driving the growth of the market. The growing prevalence of chronic lung disorders and the availability of advanced diagnostic facilities are resulting in the increased demand for emphysema treatments. Moreover, factors such as increasing sedentary lifestyles, growing urbanization and industrialization, and rising pollution levels are further propelling market expansion. Additionally, the growing research and development activities and the advancements in the medical sector are expected to impact the market dynamics positively.
Emphysema Treatment Market Growth Drivers
Increasing Prevalence of Emphysema Drives Market Growth
In the United States, around 14 million people are affected by emphysema, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is reported slightly lower in white female smokers and African Americans. The severity of the emphysema is substantially higher in coal worker pneumoconiosis, irrespective of smoking status. The rising incidence of emphysema, as a result of an increase in cigarette smoking and environmental pollution, is expected to fuel the market growth.
Emphysema Treatment Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Rising Launch of Generic Medications to Affect the Market Landscape Significantly
The increasing availability of generic treatments is projected to impact the market growth. For instance, in July 2023 , Viatris Inc. (an American global pharmaceutical company) and Kindeva Drug Delivery L.P. (a pharmaceutical contract development and manufacturing organization (CDMO)) announced the launch of its drug-device combination product Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, which is the first generic version of AstraZeneca’s Symbicort. Breyna is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD), including emphysema and/or chronic bronchitis.
Increased Adoption of Combination Therapies Poised to Augment Emphysema Treatment Market Demand
One of the major market trends is the rising preference for combination therapies, such as long-acting bronchodilators paired with inhaled corticosteroids. These combination treatments not only help in managing the symptoms more effectively but can also slow the progression of emphysema and the frequency of exacerbations, thereby improving the patient’s quality of life. The rising integration of combination therapies into treatment protocols is likely to augment the market demand.
Increased Research to Elevate the Emphysema Treatment Market Value
In January 2024 , a study published in JCI Insight revealed that a novel KF4 antibody that works by blocking chymotrypsin-like elastase 1 (CELA1) can significantly reduce lung damage as a result of diseases such as chronic obstructive pulmonary disease (COPD) and age-related emphysema in mice. Such research activities that show potential in slowing emphysema progression are set to elevate the market value in the coming years.
Advancements in Treatment Options to Boost Emphysema Treatment Market Size
The rising advancements in treatment options are poised to shape the market landscape positively. Lung volume reduction surgeries (LVRS) and procedures like endobronchial valve placement are rising in popularity as they are less invasive in nature compared to traditional methods for the treatment of severe emphysema. In addition, the emergence of biologic therapies targeting specific inflammatory pathways is anticipated to boost the market size in the forecast period.
Emphysema Treatment Market Segmentation
Market Breakup by Type
- Centriacinar
- Panacinar
- Paraseptal
- Others
- Medication
- Bronchodilators
- Steroids
- Others
- Surgery
- Others
- Oral
- Parenteral
- Others
- Hospitals
- Homecare Settings
- Specialty Clinics
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
The Type Segment is Anticipated to Witness Substantial Growth
Based on the type, the market is segmented into centriacinar, panacinar, and paraseptal, among others. Centriacinar dominates the market share as it is the most common type of emphysema, starting in the respiratory bronchioles and affecting the upper half of the lungs. This emphysema type is usually associated with long-term cigarette smoking. On the other hand, panacinar emphysema is caused by a rare genetic disease called homozygous alpha-1 antitrypsin deficiency. It typically occurs in the lower half of the lungs.
Emphysema Treatment Market Analysis by Region
The market segmentation by region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is one of the major markets for emphysema treatment owing to the high prevalence of chronic obstructive pulmonary disease (COPD) and increasing environmental pollution in the region. The availability of advanced treatments such as minimally invasive procedures and biologic therapies also benefits the market growth. Moreover, the presence of a robust regulatory framework and increasing focus on respiratory health is poised to aid market expansion in the country.
Leading Players in the Emphysema Treatment Market
The key features of the market report comprise patent analysis, grants analysis, clinical trial analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:
Pfizer Inc.
American multinational pharmaceutical industry company Pfizer is one of the leading players in the market. SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is a prescription medication developed by Pfizer that helps in the management of symptoms of chronic obstructive pulmonary disease (COPD) including emphysema.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd., headquartered in Basel, Switzerland, has a prominent presence in the market. The company is engaged in introducing new treatments for emphysema by investing in the clinical development of potential medications such as the monoclonal antibody astegolimab.
Mylan N.V.
Mylan N.V., a global healthcare company developing generic and specialty pharmaceuticals, merged with Pfizer's off-patent medicine division (Upjohn) to form Viatris. The company is focused on advancing respiratory care by leveraging strategic partnerships and collaborations with other market players.
Fresenius Kabi AG
Headquartered in Bad Homburg, Germany, Fresenius Kabi AG is a key market player that manufactures and commercializes infusion therapy and clinical nutrition products.
Other key players in the market include Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc, Bayer AG, Intersect ENT, Inc., and Sun Pharmaceutical Industries Ltd.
Key Questions Answered in the Emphysema Treatment Market Report
- What was the emphysema treatment market value in 2023?
- What is the emphysema treatment market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on type?
- What is the market breakup based on treatment type?
- What is the market breakup by treatment channel?
- What are the major distribution channels in the market?
- What are the major factors aiding the emphysema treatment market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which regional market is expected to lead the market share in the forecast period?
- Which country is expected to experience expedited growth during the forecast period?
- How do the prevalence and incidence of emphysema affect the market landscape?
- What are the major emphysema treatment market trends?
- How does the rise in the geriatric population impact the market size?
- Which type will dominate the market share?
- Which treatment type is expected to have a high market value in the coming years?
- Which treatment channel will experience the highest demand in the market segment?
- Which distribution channel is projected to contribute to the highest market growth?
- Who are the key players involved in the emphysema treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Emphysema Treatment Market Overview: 8 Major Market
- 3.1 Emphysema Treatment Market Historical Value (2018-2024)
- 3.2 Emphysema Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Emphysema Treatment: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Therapy Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Therapy Success Rate
- 7 Emphysema Treatment Market Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 U.S.
- 7.1.1.2 U.K.
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Mortality by Country
- 7.1.2.1 U.S.
- 7.1.2.2 U.K.
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate by Country
- 7.1.3.1 U.S.
- 7.1.3.2 U.K.
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Emphysema Treatment Market Landscape: 8 Major Market*
- 8.1 Emphysema Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Emphysema Treatment Market: Product Landscape
- 8.2.1 Analysis by Type
- 8.2.2 Analysis by Treatment Type
- 8.2.3 Analysis by Route of Administration
- 9 Emphysema Treatment Market Challenges and Unmet Needs
- 9.1 Therapy Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Therapy
- 11 Emphysema Treatment Market: Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Emphysema Treatment Market Segmentation: 8 Major Markets
- 12.1 Emphysema Treatment Market (2018-2034) by Type
- 12.1.1 Market Overview
- 12.1.2 Centriacinar
- 12.1.3 Panacinar
- 12.1.4 Paraseptal
- 12.1.5 Others
- 12.2 Emphysema Treatment Market (2018-2034) by Treatment Type
- 12.2.1 Market Overview
- 12.2.2 Medication
- 12.2.2.1 Bronchodilators
- 12.2.2.2 Steroids
- 12.2.2.3 Others
- 12.2.3 Surgery
- 12.2.4 Others
- 12.3 Emphysema Treatment Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Emphysema Treatment Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Homecare Settings
- 12.4.4 Specialty Clinics
- 12.4.5 Others
- 12.5 Emphysema Treatment Market (2018-2034) by Distribution Channel
- 12.5.1 Market Overview
- 12.5.2 Hospital Pharmacy
- 12.5.3 Retail Pharmacy
- 12.5.4 Online Pharmacy
- 12.5.5 Others
- 12.6 Emphysema Treatment Market (2018-2034) by Region
- 12.6.1 Market Overview
- 12.6.2 United States
- 12.6.3 EU-4 and the United Kingdom
- 12.6.3.1 Germany
- 12.6.3.2 France
- 12.6.3.3 Italy
- 12.6.3.4 Spain
- 12.6.3.5 United Kingdom
- 12.6.4 Japan
- 12.6.5 India
- 13 United States Emphysema Treatment Market (218-2034)
- 13.1 United States Emphysema Treatment Market Historical Value (2018-2024)
- 13.2 United States Emphysema Treatment Market Forecast Value (2025-2034)
- 13.3 United States Emphysema Treatment Market (2018-2034) by Type
- 13.3.1 Market Overview
- 13.3.2 Centriacinar
- 13.3.3 Panacinar
- 13.3.4 Paraseptal
- 13.3.5 Others
- 13.4 United States Emphysema Treatment Market (2018-2034) by Treatment Type
- 13.4.1 Market Overview
- 13.4.2 Medication
- 13.4.2.1 Bronchodilators
- 13.4.2.2 Steroids
- 13.4.2.3 Others
- 13.4.3 Surgery
- 13.4.4 Others
- 13.5 United States Emphysema Treatment Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 United States Emphysema Treatment Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals
- 13.6.3 Homecare Settings
- 13.6.4 Specialty Clinics
- 13.6.5 Others
- 13.7 United States Emphysema Treatment Market (2018-2034) by Distribution Channel
- 13.7.1 Market Overview
- 13.7.2 Hospital Pharmacy
- 13.7.3 Retail Pharmacy
- 13.7.4 Online Pharmacy
- 13.7.5 Others
- 14 EU-4 and United Kingdom Emphysema Treatment Market (218-2034)
- 14.1 EU-4 and United Kingdom Emphysema Treatment Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Emphysema Treatment Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Type
- 14.3.1 Market Overview
- 14.3.2 Centriacinar
- 14.3.3 Panacinar
- 14.3.4 Paraseptal
- 14.3.5 Others
- 14.4 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Treatment Type
- 14.4.1 Market Overview
- 14.4.2 Medication
- 14.4.2.1 Bronchodilators
- 14.4.2.2 Steroids
- 14.4.2.3 Others
- 14.4.3 Surgery
- 14.4.4 Others
- 14.5 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals
- 14.6.3 Homecare Settings
- 14.6.4 Specialty Clinics
- 14.6.5 Others
- 14.7 EU-4 and United Kingdom Emphysema Treatment Market (2018-2034) by Distribution Channel
- 14.7.1 Market Overview
- 14.7.2 Hospital Pharmacy
- 14.7.3 Retail Pharmacy
- 14.7.4 Online Pharmacy
- 14.7.5 Others
- 15 Japan Emphysema Treatment Market
- 15.1 Japan Emphysema Treatment Market Historical Value (2018-2024)
- 15.2 Japan Emphysema Treatment Market Forecast Value (2025-2034)
- 15.3 Japan Emphysema Treatment Market (2018-2034) by Type
- 15.3.1 Market Overview
- 15.3.2 Centriacinar
- 15.3.3 Panacinar
- 15.3.4 Paraseptal
- 15.3.5 Others
- 15.4 Japan Emphysema Treatment Market (2018-2034) by Treatment Type
- 15.4.1 Market Overview
- 15.4.2 Medication
- 15.4.2.1 Bronchodilators
- 15.4.2.2 Steroids
- 15.4.2.3 Others
- 15.4.3 Surgery
- 15.4.4 Others
- 15.5 Japan Emphysema Treatment Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Japan Emphysema Treatment Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals
- 15.6.3 Homecare Settings
- 15.6.4 Specialty Clinics
- 15.6.5 Others
- 15.7 Japan Emphysema Treatment Market (2018-2034) by Distribution Channel
- 15.7.1 Market Overview
- 15.7.2 Hospital Pharmacy
- 15.7.3 Retail Pharmacy
- 15.7.4 Online Pharmacy
- 15.7.5 Others
- 16 India Emphysema Treatment Market
- 16.1 India Emphysema Treatment Market Historical Value (2018-2024)
- 16.2 India Emphysema Treatment Market Forecast Value (2025-2034)
- 16.3 India Emphysema Treatment Market (2018-2034) by Type
- 16.3.1 Market Overview
- 16.3.2 Centriacinar
- 16.3.3 Panacinar
- 16.3.4 Paraseptal
- 16.3.5 Others
- 16.4 India Emphysema Treatment Market (2018-2034) by Treatment Type
- 16.4.1 Market Overview
- 16.4.2 Medication
- 16.4.2.1 Bronchodilators
- 16.4.2.2 Steroids
- 16.4.2.3 Others
- 16.4.3 Surgery
- 16.4.4 Others
- 16.5 India Emphysema Treatment Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 India Emphysema Treatment Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals
- 16.6.3 Homecare Settings
- 16.6.4 Specialty Clinics
- 16.6.5 Others
- 16.7 India Emphysema Treatment Market (2018-2034) by Distribution Channel
- 16.7.1 Market Overview
- 16.7.2 Hospital Pharmacy
- 16.7.3 Retail Pharmacy
- 16.7.4 Online Pharmacy
- 16.7.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 INDIA CDSCO
- 17.5 JAPAN PMDA
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 18.7 Analysis by Key Players
- 19 Clinical Trial Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grant Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Product
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Pfizer Inc.
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Developments
- 23.2.5 Certifications
- 23.3 F. Hoffmann-La Roche Ltd.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Developments
- 23.3.5 Certifications
- 23.4 Mylan N.V.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Developments
- 23.4.5 Certifications
- 23.5 Fresenius Kabi AG
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Developments
- 23.5.5 Certifications
- 23.6 Hikma Pharmaceuticals PLC
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Developments
- 23.6.5 Certifications
- 23.7 Novartis AG
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Developments
- 23.7.5 Certifications
- 23.8 Teva Pharmaceutical Industries Ltd.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Developments
- 23.8.5 Certifications
- 23.9 Bristol Myers Squibb Company
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Developments
- 23.9.5 Certifications
- 23.10 GSK Plc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Developments
- 23.10.5 Certifications
- 23.11 Bayer AG
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Developments
- 23.11.5 Certifications
- 23.12 Sun Pharmaceutical Industries Ltd.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Developments
- 23.12.5 Certifications
- 23.13 Intersect ENT, Inc.
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Company News and Developments
- 23.13.5 Certifications
- 24 Emphysema Treatment Market – Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
